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Genetic variation of human immunodeficiency virus (HIV-1) represents a major obstacle for AIDS vaccine
development. To decrease the genetic distances between candidate immunogens and field virus strains, we have
designed and synthesized an artificial group M consensus env gene (CON6 gene) to be equidistant from
contemporary HIV-1 subtypes and recombinants. This novel envelope gene expresses a glycoprotein that binds
soluble CD4, utilizes CCR5 but not CXCR4 as a coreceptor, and mediates HIV-1 entry. Key linear, confor-
mational, and glycan-dependent monoclonal antibody epitopes are preserved in CON6, and the glycoprotein is
recognized equally well by sera from individuals infected with different HIV-1 subtypes. When used as a DNA
vaccine followed by a recombinant vaccinia virus boost in BALB/c mice, CON6 env gp120 and gp140CF elicited
gamma interferon-producing T-cell responses that recognized epitopes within overlapping peptide pools from
three HIV-1 Env proteins, CON6, MN (subtype B), and Chn19 (subtype C). Sera from guinea pigs immunized
with recombinant CON6 Env gp120 and gp140CF glycoproteins weakly neutralized selected HIV-1 primary
isolates. Thus, the computer-generated “consensus” env genes are capable of expressing envelope glycoproteins
that retain the structural, functional, and immunogenic properties of wild-type HIV-1 envelopes.
The high level of genetic variability of HIV-1 poses a major
hurdle for AIDS vaccine development. Genetic differences
among HIV-1 groups M, N, and O are extensive, ranging from
30 to 50% in the gag and env genes, respectively (14, 20, 33, 35).
HIV-1 also frequently recombines among different subtypes to
create circulating recombinant forms (CRFs) and novel recom-
binants (5, 27, 28). To overcome the challenge of HIV-1 di-
versity, “centralized” HIV-1 genes have been proposed to use
in HIV-1 immunogen design. These strategies include using
consensus sequences, the most frequent base found in a given
position, or ancestral or center-of-the-tree sequences, both
modeled from phylogenetic trees (9, 10, 12, 18, 23, 24). A
sequence that is central to all HIV-1 epidemic strains within
group M would increase amino acid similarities with contem-
porary field HIV-1 isolates relative to intersubtype distances
and therefore might be useful in a setting where diverse sub-
types and recombinants are cocirculating (12). However, be-
cause centralized genes are artificially made, it has been of
great concern that these genes may not be able to fold into
native conformations, perform biological functions of native
Env, preserve Env antigenic epitopes, or induce salutary im-
mune responses when used as immunogens. To address these
concerns, we synthesized an artificial group M consensus env
gene (CON6 gene) and studied its biological, antigenic, and
immunological properties. Our studies demonstrated that
CON6 proteins are biologically functional and are immuno-
genic for eliciting immune responses to wild-type HIV-1
strains.
MATERIALS AND METHODS
Expression of CON6 gp120 and gp140CF proteins by using rVVs. To generate
secreted forms of group M consensus env gene (CON6) envelope glycoproteins,
CON6 gp120 and gp140CF plasmids were constructed by introducing stop
codons after the gp120 cleavage site (REKR) and before the membrane-span-
ning domain (YIKIFIMIVGGLIGLRIVFAVLSIVN), respectively. The gp120/
gp41 cleavage site and fusion domain of gp41 were deleted in the gp140CF
protein. Recombinant vaccinia viruses (rVVs) containing CON6 env genes were
generated as described previously (21) and confirmed by PCR and nucleotide
sequence analysis. Recombinant CON6 gp120 and gp140CF glycoproteins were
purified with agarose Galanthus nivalis lectin beads (Vector Labs, Burlingame,
Calif.) and stored at 70°C until use.
MAbs and gp120 wild-type envelopes. Human monoclonal antibodies (MAbs)
known to bind conformational epitopes on gp120 (A32), the gp120 V3 loop
(F39F), and the CCR5 binding site (17b) were kindly provided by James Rob-
inson (Tulane Medical School, New Orleans, La.) (37, 38). MAbs 2F5, 447-52D,
IgG1b12, and 2G12 and soluble CD4 (sCD4) were obtained from the National
Institutes of Health (NIH) AIDS Research and Reference Reagent Program
(Bethesda, Md.) (13, 25, 26, 34). T8 is a murine MAb that maps to the gp120 C1
region (a gift from P. Earl, NIH). BaL (subtype B), 96ZM651 (subtype C), and
93TH975 (subtype E) gp120s were provided by QBI, Inc., and the Division of
AIDS, NIH. 92U037 (subtype A) and 93BR029 (subtype F) gp140 proteins
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(secreted and uncleaved) were purified from CHO cell lines (obtained from the
Centralised Facility for AIDS Reagents, National Institute for Biological Stan-
dards and Control [NIBSC], Hertfordshire, United Kingdom) by using agarose
Galanthus nivalis lectin beads (Vector Labs).
BN-PAGE analysis. Blue native polyacrylamide gel electrophoresis (BN-
PAGE) analysis of CON6 gp120 and gp140CF proteins was carried out according
to the methods described by others (30, 31), with minor modifications due to the
highly basic pIs of HIV-1 Env proteins. Lectin column-purified proteins were
diluted in a buffer containing 50 mM MOPS (morpholinepropanesulfonic acid),
50 mM Tris-HCl (pH 7.7), 20% glycerol, and 0.05% Coomassie blue. Protein
samples were loaded onto a 3 to 8% Tris-acetate NuPAGE gel (Invitrogen,
Carlsbad, Calif.), and electrophoresis was carried out for 1.5 h at 150 V with 50
mM MOPS–50 mM Tris-HCl (pH 7.7)–0.03% Coomassie blue as the cathode
running buffer and 50 mM MOPS–50 mM Tris HCl (pH 7.7) as the anode buffer.
Thyroglobulin, ferritin, catalase, and alcohol dehydrogenase (Amersham Bio-
sciences) were included in each run, as was HIV-1 89.6 gp120 Env monomer.
Surface plasmon resonance biosensor measurements and ELISA. Surface
plasmon resonance biosensor measurements were determined on a BIAcore
3000 instrument, and data analysis was performed with BIAevaluation 3.0 soft-
ware (BIAcore Inc, Upsaala, Sweden). Anti-gp120 MAbs (T8, A32, 17b, and
2G12) or sCD4 in 10 mM Na-acetate buffer (pH 4.5) were directly immobilized
to a CM5 sensor chip, using a standard amine coupling protocol for protein
immobilization. Fast protein liquid chromatography-purified CON6 gp120
monomer or gp140CF oligomer recombinant proteins were flowed over CM5
sensor chips at concentrations of 100 and 300 g/ml, respectively. Binding of
CON6 envelope proteins was monitored in real time at 25°C with a continuous
flow of phosphate-buffered saline (150 mM NaCl, 0.005% surfactant P20 [pH
7.4]) at 10 to 30 l/min. Enzyme-linked immunosorbent assay (ELISA) was
performed to determine the reactivities of various MAbs to CON6 gp120 and
gp140CF proteins as described previously (16). For assay of human MAb binding
to gp120 or gp140 proteins, end point titers were defined as the highest titer of
any MAb (beginning at 20 g/ml) at which the MAb bound CON6 gp120 and
gp140CF Env proteins 3-fold over the background control (nonbinding human
MAb).
Measurement of kinetics of binding of CON6 Env proteins to sCD4 and
anti-HIV-1 MAbs. Soluble CD4 and MAbs (A32 and T8) were immobilized on
individual flow cells of the CM5 sensor chip. Association (on) and dissociation
(off) rates were measured by injecting serial dilutions of Env proteins (1.3 to 83
nM for 89.6 gp120, 34 to 1100 nM for CON6 gp120, and 62.5 to 1000 nM for
CON6 gp140CF) over each ligand surface at a flow rate of 20 l/min. For kinetic
analysis, nonspecific signal was subtracted from a control immunoglobulin G
(IgG) surface (mouse IgG). Rate constants were derived from global curve-
fitting analysis, using a Langmuir 1:1 binding model.
Infectivity and coreceptor usage. HIV-1/SG3env and CON6 or control env
plasmids were cotransfected into human 293T cells. Pseudotyped virion prepa-
rations were harvested, filtered, analyzed for p24 content (Bechman Coulter,
Inc., Miami, Fla.), and then used to infect JC53-BL cells (using serial fivefold
dilutions) (8, 36). JC53-BL cells express CD4, CCR5, and CXCR4 receptors and
contain a -galactosidase gene and a firefly luciferase gene stably integrated
under the transcriptional control of an HIV-1 long terminal repeat. To deter-
mine the coreceptor usage of the CON6 env gene, JC53-BL cells were treated
with 1.2 M AMD3100 and 4 M TAK799 for 1 h at 37°C and then infected with
equal amounts of p24 (5 ng) of each Env-pseudotyped virus. Infectivity in the
absence of the blocking agent was set as 100%. Blockage efficiency was expressed
as the percentage of the infectivity of the virus in the absence of blocking agent.
Immunizations. All animals were housed in the Duke University Animal
Facility under Association for Assessment and Accreditation of Laboratory An-
imal Care guidelines with animal use protocols approved by the Duke University
Animal Use and Care Committee. For induction of antienvelope antibodies,
each of four outbred guinea pigs (Harlan Sprague, Inc., Chicago, Ill.) was given
100 g of either purified CON6 gp120 or gp140CF subcutaneously in RIBI-CWS
adjuvant every 3 weeks (total of five immunizations). Serum samples were heat
inactivated (56°C, 1 h) and stored at 20°C until use. For induction of antien-
velope T-cell responses, 6- to 8-week-old female BALB/c mice (Frederick Can-
cer Research and Developmental Center, National Cancer Institute, Frederick,
Md.) were immunized intramuscularly (five mice per group) with 50 g of
plasmid DNA three times at 3-week intervals. Three weeks after the last DNA
immunization, mice were boosted with 107 PFU of rVV expressing either gp120
or gp140CF glycoprotein.
Neutralization assays. Neutralization assays were performed with either an
MT-2 assay as described previously (3) or a luciferase-based multiple-replication-
cycle HIV-1 infectivity assay in 5.25.GFP.Luc.M7 cells with a panel of HIV-1
primary isolates (3, 4). In the luciferase-based assay, neutralizing antibodies were
measured as a function of a reduction in luciferase activity in 5.25.EGFP.Luc.M7
cells (kindly provided by Nathaniel R. Landau, Salk Institute, La Jolla, Calif.)
(2). Five hundred 50% tissue culture infectious doses of cell-free virus was
incubated (1 h, 37°C) with the indicated serum dilutions in 150 l in triplicate in
96-well flat-bottom culture plates. The 5.25.EGFP.Luc.M7 cells were suspended
at a density of 5 105/ml in medium containing DEAE-dextran (10 g/ml). Cells
(100 l) were added until 10% of cells in control wells (no test serum sample)
were positive for green fluorescent protein expression by fluorescence micros-
copy. The suspension of cells (50 l) was transferred to 96-well white solid plates
(Costar, Cambridge, Mass.) for measurement of luciferase activity by using
Bright-Glo substrate (Promega, Madison, Wis.) on a Wallac 1420 Multilabel
Counter (Perkin-Elmer Life Sciences, Boston, Mass.). Neutralization titers in the
luciferase assays were those where relative luciferase units were reduced by
50% compared to corresponding preimmune serum. Neutralization titers in
the MT-2 assay were determined by a 50% reduction in virus-induced cell killing,
which corresponds to a 90% reduction in infectivity (3). Only samples with
titers beyond 1:20 (i.e.,1:30) and neutralization titers three times over prebleed
levels were considered positive. Absorption of sera with HIV-1 V3 peptides was
performed at a saturating final peptide concentration of 50 g/ml.
Enzyme-linked immune spot assay. Spleens were harvested 2 weeks after the
rVV boost, and single-cell suspensions of splenocytes from individual immunized
mice were prepared by mincing and forcing through a 70-m nylon cell strainer
(BD Labware, Franklin Lakes, N.J.). Overlapping Env peptides of CON6 gp140
(159 peptides, 15-mers overlapping by 11) were purchased from Boston Bio-
science, Inc. (Royal Oak, Mich.). Overlapping Env peptides of MN gp140 (sub-
type B; 170 peptides, 15-mers overlapping by 11) and Chn19 gp140 (subtype C;
69 peptides, 20-mers overlapping by 10) were obtained from the NIH AIDS
Research and Reference Reagent Program. Splenocytes from each mouse (five
mice per group) were stimulated in vitro with CON6 overlapping Env peptides
pools. Ninety-six-well polyvinylidene difluoride plates (MultiScreen-IP, Milli-
pore, Billerica, Mass.) were coated with an anti-gamma interferon (anti-IFN-	)
MAb (5 g/ml) (AN18; Mabtech, Stockholm, Sweden). After the plates were
blocked at 37°C for 2 h with complete HEPES-buffered RPMI medium, 50 l of
the pooled overlapping envelope peptides (two CON6 pools with 79 or 80
peptides in each pool, two MN pools with 85 peptides in each pool, and one
Chn19 pool with 69 peptides) at a final concentration of 5 g of each peptide per
ml was added to the plate, and then 50 l of splenocytes at a concentration of
107/ml was added to the wells in duplicate and incubated for 16 h at 37°C with
5% CO2. The plates were incubated with 100 l of a 1:1,000 dilution of strepta-
vidin-alkaline phosphatase (Mabtech), and purple spots were developed with 100
l of 5-bromo-4-chloro-3-indolyl--D-galactopyranoside–nitroblue tetrazolium
(Plus) alkaline phosphatase substrate (Moss, Pasadena, Md.). Spot-forming cells
(SFCs) were measured with an Immunospot counting system (CTL Analyzers,
Cleveland, Ohio). Total responses for each envelope peptide pool are expressed
as SFCs per 106 splenocytes.
RESULTS
CON6 envelope gene design, construction, and expression.
A synthetic group M consensus env gene (CON6 gene) was
constructed by generating consensus sequences of env genes
for each HIV-1 subtype from sequences in the Los Alamos
HIV sequence database and then generating a consensus se-
quence of all subtype consensuses, thus avoided biasing the
group M consensus towards heavily sequenced subtypes (12,
19). The hypervariable regions (V1, V2, V4, and V5) in the env
gene evolve by rapid insertion and deletion and not by point
mutation. Consensus sequences were not generated for these
regions. Instead, five highly variable regions (V1, V2, V4, V5,
and a region in the cytoplasmic domain of gp41) from a
CRF08_BC recombinant strain (98CN006) were then used to
fill in the nonconsensus variable regions in the CON6 se-
quence, with the thought that these regions might be able to
act coordinately to recreate a functional, properly folded en-
velope when embedded in the context of the M group consen-
sus sequence. The V3 region generally evolves by point muta-
tion with relatively few insertions and deletions, and so in
CON6 Env it is based on the group M consensus and not on
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98CN006 (Fig. 1A). For high levels of expression, the codons
of the CON6 env gene were optimized based on codon usage of
highly expressed human genes (1, 15). The codon-optimized
CON6 env gene (gp160) was constructed and subcloned into
pcDNA3.1 DNA at EcoRI and BamHI sites (11). High levels
of protein expression were confirmed by Western blot analysis
after transfection into 293T cells (not shown). To obtain sol-
uble recombinant CON6 Env proteins for biological charac-
terization and use as immunogens, rVVs were generated to
express secreted gp120 and gp140CF (Fig. 1B). Both proteins
were purified from the supernatants of rVV-infected 293T cells
by using agarose Galanthus nivalis lectin beads. The purity of
each protein was 95% as determined by sodium dodecyl
sulfate(SDS)-PAGE analysis (Fig. 1C).
CON6 gp160 is biologically active and uses CCR5 as its
coreceptor. To examine whether the synthetic group M con-
sensus env gene expressed a glycoprotein that could
pseudotype an env-deficient HIV-1 provirus, CON6 gp160 was
cotransfected with HIV-1/SG3env (along with the NL4-3 and
YU2 gp160 genes for controls) into human 293T cells, and the
resulting supernatants were analyzed for the presence of in-
fectious viruses in the JC53-BL cell assay (8, 36). JC53-BL cells
express CD4, CCR5, and CXCR4 receptors and contain a
-galactosidase gene stably integrated under the transcrip-
FIG. 1. Generation and expression of the group M consensus env gene (CON6). (A) The complete amino acid sequence of CON6 gp160 is
shown. The five regions from the wild-type CRF08_BC (98CN006) env gene are indicated by underlined letters. Variable regions are indicated by
brackets above the sequences. Potential N-liked glycosylation sites are highlighted with boldface letters. The deletion in gp140CF construct is
shown in a box. (B) Constructs of CON6 gp120 and gp140CF. (C) Expression of CON6 gp120 and gp140CF. CON6 gp120 and gp140CF were
purified from the cell culture supernatants of rVV-infected 293T cells with agarose Galanthus nivalis lectin columns. Both gp120 and gp140CF were
separated on a 6% SDS-polyacrylamide gel under reducing conditions and stained with Coomassie blue.
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tional control of an HIV-1 long terminal repeat. These cells
can thus be used to quantify the infectious titers of
pseudotyped viral stocks by staining for -galactosidase expres-
sion and counting the number of blue cells (infectious units)
per microgram of p24 of input virus. As shown in Fig. 2A,
CON6-derived glycoprotein conferred infectivity to HIV-1/
SG3env when complemented in trans; however, in three in-
dependent experiments, the resulting CON6 Env pseudovirion
stocks were reduced in their infectivity by 1 to 2 log units
compared to wild-type NL4-3 or YU2 Env pseudovirions.
Experiments were next performed to determined the core-
ceptor usage of pseudovirions containing the CON6 gp160
envelope gene. When treated with the CXCR4-blocking agent
AMD3100, the infectivity of NL4-3 Env pseudovirions was
blocked, while the infectivity of YU2 or CON6 Env pseudoviri-
ons was not inhibited (Fig. 2B). In contrast, when treated with
the CCR5-blocking agent TAK779, the infectivity of NL4-3
Env pseudovirions was not affected, while the infectivity of
YU2 or CON6 Env pseudovirions was inhibited. When treated
with both blocking agents, the infectivity of all pseudovirions
was inhibited. Taken together, these data showed that the
CON6 env gene expressed a glycoprotein that was incorpo-
rated into virus particles, mediated virus entry (albeit ineffi-
ciently) into appropriate target cells, and used the CCR5 co-
receptor for its entry into target cells.
Oligomeric status of CON6 gp120 and gp140CF proteins.
Upon size exclusion chromatography, dimer and higher oligo-
meric forms of CON6 gp120 and gp140CF, respectively, were
detected (data not shown). To more precisely determine the
oligomeric status of CON6 Env proteins, we analyzed both
CON6 gp120 and gp140CF by BN-PAGE analysis as previ-
ously reported (29, 31). A representative result of three deter-
minations is presented in Fig. 3. In the blue native gel, CON6
gp120 proteins migrated as monomers and dimers. However,
formation of dimers is not unique to this consensus Env pro-
tein, as Center et al. have previously shown that the wild-type
HIV-1 Env V2 domain mediates disulfide-linked gp120 dimer
formation (6). Dimer formation of CON6 gp120 and gp140CF
Env was also disulfide linkage mediated (not shown). On BN-
PAGE, the size of CON6 gp120 monomers was very similar to
that of 89.6 gp120 monomers. Dimers and oligomeric species
(trimers and tetramers) were observed for CON6 gp140CF
proteins in the BN-PAGE analysis (Fig. 3). Dimers and trimers
of CON6 gp140CF were the most abundant multimer forms,
while a lesser gp140CF tetrameric band was detected.
FIG. 2. Infectivity and coreceptor usage of CON6 envelope.
(A) CON6 and control env plasmids were cotransfected with an HIV-
1/SG3env backbone into human 293T cells to generate Env
pseudovirions. Culture supernatants were analyzed for p24 content
and then used to infect JC53-BL cells (using serial fivefold dilutions).
The infectivity was determined by counting the number of blue cells
(infectious units) per microgram of p24 of pseudovirions after staining
the infected cells for -galactosidase expression. (B) Coreceptor usage
of the CON6 env gene was determined on JC53-BL cells treated with
AMD3100 and/or TAK799 for 1 h (37°C) and then infected with equal
amounts of p24 (5 ng) of each Env pseudovirion. Infectivity in the
control group (no blocking agent) was set as 100%. The blockage
efficiency was expressed as the percentage of the infectivity of the virus
in the absence of the blocking agent. Data shown are means 
 stan-
dard deviations from three independent experiments.
FIG. 3. BN-PAGE analysis of CON6 gp120 and gp140CF proteins.
Affinity-purified 89.6 gp120, CON6 gp120, and CON6 gp140CF pro-
teins were loaded onto a 3 to 8% Tris-acetate NuPAGE gel, and
electrophoresis was carried out for 1.5 h at 150 V with 50 mM
MOPS–50 mM Tris-HCl (pH 7.7)–0.03% Coomassie blue as the cath-
ode running buffer and 50 mM MOPS–50 mM Tris-HCl (pH 7.7) as
the anode buffer.
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The CD4 binding domain and other HIV-1 epitopes are
preserved on CON6 proteins. To examine the folding of CON6
env gene-derived gp120 and gp140CF glycoproteins, CON6
proteins were assayed for their ability to bind to sCD4 as well
as to several well-characterized anti-gp120 MAbs and to un-
dergo CD4-induced conformational changes. First, BIAcore
CM5 sensor chips were coated with either sCD4 or MAbs to
monitor their binding to CON6 Env proteins. Both monomeric
CON6 gp120 and trimeric gp140CF efficiently bound sCD4
and anti-gp120 MAbs T8, 2G12, and A32, but not MAb 17b
(Fig. 4A and B). MAb 17b binds to a CD4-inducible epitope
located near the CCR5 binding site of gp120; the binding of
either sCD4 or A32 to wild-type gp120 can cause the confor-
mational change that exposes the 17b epitope (37, 38). To
determine whether the 17b epitope could also be induced on
purified CON6 Envs, sCD4, A32, or T8 was applied to sensor
chips to capture CON6 gp120 or gp140CF, and then 17b bind-
ing activity was monitored. As shown in Fig. 4C and D, both
CON6 gp120 and gp140CF were induced to undergo confor-
mational changes and bound 17b only following binding to
sCD4 and A32 but not T8.
Both CON6 gp120 and gp140CF bound to sCD4, T8, and
A32 with high affinity (Kd in the nanomolar range) as deter-
mined by measuring the on and off rates of binding in BIAcore
analysis (Table 1). The bindings of CON6 gp120 and gp140CF
to immobilized sCD4 were similar to each other (34.7 and 13.8
nM, respectively) but lower than that observed with 89.6 gp120
(5.7 nM). The differences were largely in the on rates (ka), with
CON6 Env proteins binding with lower on rates. Similar bind-
ing activities of CON6 Env proteins in on rates were also
observed when rates of binding to A32 and T8 were compared.
However, it is important to note that the reported affinity of
HIV-1 gp120 proteins binding to sCD4 spans a relatively wider
range, from about 1 to 2 nM (89.6, YU2, and ADA) to 20 to 28
nM (JRFL and BH10) (17, 22, 39, 40). Thus, the affinities for
CON6 gp120 and gp140CF fall within this range.
In an ELISA, both CON6 gp120 and gp140CF bound well to
neutralizing V3 MAbs 447-52D and F39F and to the potent
neutralizing CD4 binding site MAb IgG1b12. MAb 2F5, which
neutralizes HIV-1 primary isolates by binding to a C-terminal
gp41 epitope, also bound well to CON6 gp140CF (Fig. 4E).
Reaction of CON6 gp120 with sera of different subtypes. To
determine whether multiple subtype linear epitopes are pre-
served on CON6 gp120, a panel of recombinant Env proteins
(one each for subtypes A, B, C, F, and CRF01_AE gp120 or
gp140 protein) was assembled. Equal amounts of each Env
protein (100 ng) were loaded on SDS-polyacrylamide gels,
transferred to nitrocellulose, and reacted with subtype A
through G patient sera (1:1,000 dilution) in Western blot as-
says. For each HIV-1 subtype, four to six patient sera were
tested. One serum representative of each subtype is shown in
Fig. 5. Whereas sera of all subtypes tested showed variable
reactivities among Envs of different subtypes in the panel,
patient sera of all subtypes reacted equally well with CON6
gp120 Env protein, demonstrating that cross-reactive HIV-1
Env epitopes recognized by patient sera were well preserved
on the CON6 Env protein.
Induction of T-cell responses to CON6 envelope overlapping
peptides. T-cell immune responses induced by CON6 envelope
immunogens were assayed against overlapping CON6 Env
peptides as well as subtype B or C peptide pools (MN and
Chn19, respectively). Three groups of mice (five mice per
group) were primed with CON6 gp120, CON6 gp140CF, or
empty vector DNA control and boosted with rVV expressing
the corresponding envelope glycoproteins or a control vaccinia
virus strain (WR). IFN-	 SFCs were detected when spleno-
cytes from mice immunized with either CON6 gp120 or
gp140CF proteins were stimulated with CON6, MN, or Chn19
peptide pools (Fig. 6). The T-cell immune responses induced
by CON6 gp140CF appeared to be more robust than those
induced by CON6 gp120 for any peptide pool. These data
demonstrated that CON6 gp120 and gp140CF immunogens
were capable of inducing T-cell responses to both CON6
epitopes and to subtype B and subtype C wild-type epitopes.
Induction of antibodies that neutralize selected HIV-1 pri-
mary isolates. To determine whether CON6 envelope immu-
nogens induced antibodies that could neutralize HIV-1 pri-
mary isolates, guinea pigs were immunized with either CON6
gp120 or gp140CF protein. Sera collected after four or five
immunizations were used for neutralization assays and com-
pared to the corresponding prebleed sera (Table 2). All gp120
and gp140CF sera showed neutralization of two of eight sub-
type B primary isolates (BXO8 and SF162), and most gp120
and gp140CF sera showed weak neutralization of subtype B
isolate QH0692 and SS1196. Sporadic weak neutralization or
no neutralization was detected against SHIV SF162P3 and
SHIV89.6P, as well as against the other subtype A, B, C, D,
and CRF01_AE primary isolates tested. Thus, these data
showed that while the group M consensus CON6 envelope was
indeed capable of inducing antibodies that could neutralize
select subtype B HIV-1 primary isolates, the level of neutral-
ization was weak for all isolates neutralized except HIV-1
SF162.
Ability of group M consensus V3 peptide to absorb some
neutralizing activity of CON6 gp120 and gp140CF-induced
antibodies. To determine the contribution of the group M
consensus V3 loop antibodies to the ability to neutralize HIV-1
primary isolates and to determine the specificity of epitopes of
gp120- and gp140CF-induced antibodies for both T-cell-line-
adapted and primary HIV-1 strains, we have tested anti-gp120
and -gp140CF sera in the presence of 50 g of group M
consensus peptide (TRPNNNTRKSIHIGPGQAFYATGEIIG
DIRQAH) per ml (final concentration) for the ability to neu-
tralize HIV-1 (Tables 3 and 4). For anti-gp120 guinea pig sera,
the V3 peptide absorbed a mean of 77% of the neutralizing
activity for the TCLA strain HIV-1 MN and 53% of the activity
for the primary isolate HIV-1 SS1196, while the group M
consensus V3 peptide absorbed only 30% of the neutralizing
activity for primary isolate HIV-1 BX08 (P  0.03 for BX08
versus MN) (Table 3). Similarly, for anti-gp140CF sera, the V3
peptide absorbed 87% of anti-MN activity, 66% of anti-SS1196
activity, and only 19% of anti-BX08 activity (P 0.01 for BX08
versus MN) (Table 4). Taken together, these data demon-
strated that the neutralizing activity for group M consensus
antisera for HIV MN and to a lesser extent for SS1196 is
predominantly against the V3 loop, and specificities of anti-
bodies distinct from the V3 antibodies absorbed by the V3
peptide are responsible for the majority of CON6 Env-induced
neutralization activity for the HIV-1 primary isolate BX08.
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FIG. 4. Binding of CON6 gp120 and gp140CF to sCD4 and anti-Env MAbs. (A and B) Each of the indicated MAbs and sCD4 were covalently
immobilized to a CM5 sensor chip (BIAcore), and CON6 gp120 (A) or gp140CF (B) was injected over each surface (100 and 300 g/ml,
respectively). (C and D) To determine induction of 17b MAb binding to CON6 gp120 and gp140CF, CON6 gp120 (C) or gp140CF (D) proteins
were captured (400 to 580 response units) on individual flow cells immobilized with sCD4 or MAb A32 or T8. Following stabilization of each of
the surfaces, MAb 17b was injected and allowed to flow over each of the immobilized flow cells. (E) To determine binding of CON6 gp120 and
gp140CF to human MAbs in ELISA, titers of stock solutions of 20 g of MAbs 447-52D, F39F, A32, IgG1b12, and 2F5 were determined with
CON6 gp120 and gp140CF glycoproteins. MAbs 447-52D (V3), F39F (V3) A32 (gp120), and IgG1b12 (CD4 binding site) each bound to both
CON6 gp120 and gp140CF well, while 2F5 (anti-gp41 ELDKWAS) bound only CON6 gp140CF. The concentrations at the end point titer (end
titer where the experimental versus the control value was 3.0) with gp120 for MAb 447-52D and F39F binding were 0.003 and 0.006 g/ml,
respectively; that for MAb A32 was 0.125 g/ml; that for IgG1b12 was 0.002 g/ml; and that for 2F5 with gp140CF was 0.016 g/ml.
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DISCUSSION
In this study, we have tested a new strategy for HIV-1 im-
munogen design by generating a group M consensus env gene
(CON6 gene) with the purpose of decreasing the genetic dis-
tance between this candidate immunogen and circulating virus
strains. A critical question that this study has answered is
whether such a synthetic gene can encode an envelope glyco-
protein with antigenicity and immunogenicity properties re-
sembling those of wild-type HIV-1 envelope glycoproteins. We
have demonstrated this important proof of concept that the
synthetic group M consensus Env protein was biologically
functional, preserved many well-studied antigen epitopes,
cross-reacted with patient sera of multiple subtypes, and were
immunogenic for inducing both T- and B-cell anti-HIV-1 re-
sponses in mice or guinea pigs.
The genetic distance between the group M consensus Env
sequence and other subtype Env sequences is only about 15%,
which is half of that seen between wild-type subtypes (30%)
(12). The CON6 Env was generated by choosing the most
common amino acid at most positions in all subtypes in con-
stant and V3 regions (12, 19). Since only the most common
amino acids were selected, it was anticipated that the majority
of antibody and T-cell epitopes would be well preserved. We
postulate that polyclonal T- and B-cell responses to a consen-
sus immunogen would be likely to include a greater number of
shared epitopes with improved potential to cross-react with
circulating strains than any one natural strain. Cross-reactivity
of the CON6 Env protein to patient sera of multiple subtypes
indicated that cross-reactive antibody binding epitopes were
preserved on this artificial group M consensus Env protein.
These data suggest that the group M consensus Env protein
would be an ideal candidate for use in diagnostic test kits for
HIV-1 antibodies.
Infectivity of CON6-Env pseudovirions was demonstrated by
using a single-round infection system, although the ability to
mediate viral entry was reduced, indicating a suboptimal en-
velope conformation affecting entry and/or uncoating events.
Nonetheless, BIAcore data showed that both CON6 gp120 and
gp140CF bound sCD4 and a number of conformationally sen-
sitive MAbs that also are reactive with wild-type HIV-1 Env
proteins. The group M consensus envelope utilized the CCR5
coreceptor, which is an important consideration for a vaccine
candidate since primary HIV infections tend to be with viruses
with CCR5 usage (7, 32).
CON6 Env proteins were immunogenic for inducing both T-
and B-cell immune responses, including neutralizing antibod-
FIG. 5. Western blot analysis of Env proteins of multiple subtypes
against antisera of multiple subtypes. Equal amounts of Env proteins
(100 ng) were separated on SDS–10% polyacrylamide gels (gp120: Bal,
96ZM651, 93TH975, and CON6; gp140: 92UG37, and 93BR029). Fol-
lowing electrophoresis, proteins were transferred to nitrocellulose
membranes and reacted with sera from HIV-1-infected patients (1:
1,000). Protein-bound antibody was probed with fluorescence-labeled
secondary antibodies, and the images were scanned and recorded on
an Odyssey infrared imager (Li-Cor, Lincoln, Nebr.). Subtypes are
indicated by single letters after Env protein and serum designations.
Four to six sera were tested for each subtype, and reaction patterns
were similar among all sera from the same subtype. One representative
result for each subtype serum is shown.
FIG. 6. T-cell immune responses induced by CON6 Env immuno-
gens in mice. Splenocytes were isolated from individual immunized
mice (five mice per group). After splenocytes were stimulated in vitro
with overlapping Env peptide pools of CON6, Chn19_C, MN_B, and
medium, IFN-	-producing cells were determined by the enzyme-linked
immune spot assay. Total responses for each immunogen and peptide
pool are expressed as SFCs per million splenocytes. The values are the
means 
 standard errors of the means of IFN-	 SFCs (n  5 mice per
group).
TABLE 1. Kinetics of sCD4 and anti-HIV-1 MAb binding to
CON6 Env proteinsa
Ligand Analyte ka (M1 s1) kd (s1) Kd (nM)
sCD4 89.6 gp120 9.8 104 5.6  104 5.7
CON6 gp120 1.7 104 5.9  104 34.7
CON6 gp140 1.6 104 2.2  104 13.8
T8 89.6 gp120 3.9 104 9.5  105 2.4
CON6 gp120 1.2 104 3.0  104 25.0
CON6 gp140 1.1 104 2.0  104 19.1
A32 89.6 gp120 1.6 105 5.3  105 0.3
CON6 gp120 1.3 104 4.2  105 3.2
CON6 gp140 9.7 103 1.1  105 1.2
a ka, on rate; kd, off rate; Kd, affinity.
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ies, albeit of limited strength and breadth for the latter.
When used for immunization in mice, both CON6 gp120 and
gp140CF proteins induced T-cell immune responses to sub-
type B and subtype C wild-type Envs (Fig. 6). However,
future studies are needed to test the breadth of T-cell im-
mune responses in mice and nonhuman primates by expand-
ing the number of strains of mice and native Env overlap-
ping peptide sets tested and to directly determine whether
CON6 envelope genes are better than wild-type env genes
for induction of cross-subtype T-cell responses. These stud-
TABLE 2. Ability of group M consensus HIV-1 envelope CON6 gp120 and gp140CF proteins to induce antibodies that neutralize HIV-1
primary isolates
HIV isolate (subtype)a
Titerb with the indicated guinea pig or control
CON6 gp120 protein CON6 gp140CF protein Positive controlc
646 647 648 649 650 651 652 653 TriMab2 CD4-IgG2 HIV-positiveserum
92RW020 (A) 20 20 20 20 20 20 20 20 NTd NT 693
BAL (B) 20 20 20 20 20 200 20 20 NT NT 3307
BX08 (B) 438 326 364 417 481 480 652 246 0.7 NT 2384
BG1168 (B) 20 20 20 20 40 20 20 25 2.7 NT NT
6101 (B) 20 20 20 20 20 20 72 20 1.1 NT NT
SF162 (B) 2,146 388 110 302 235 5,502 15,098 199 NT NT 540
SS1196 (B) 246 20 185 86 381 449 333 117 NT NT 301
QH0692 (B) 31 32 34 20 20 33 30 45 0.8 NT 769
PAVO (B) 20 20 20 20 20 20 20 20 209 NT NT
SHIV 89.6P (B) 20 20 20 20 20 20 20 20 NT NT NT
SHIV SF162P3 (B) 20 30 48 20 27 20 20 20 NT 0.2 NT
DU368 (C) 25 35 62 20 20 20 20 23 NT 2.3 NT
S021 (C) 20 20 33 20 20 20 20 20 NT 803 NT
S080 (C) 24 37 70 41 20 20 20 52 NT 3.4 NT
DU179 (C) 20 20 20 20 20 20 20 540 NT 0.8 NT
S007 (C) 20 20 20 20 20 20 20 20 NT NT NT
S017 (C) 20 20 20 20 20 20 20 20 NT NT NT
TV-1 (C) 20 20 20 20 20 20 20 20 NT NT NT
93ZR001 (D) 314 170 156 20 339 339 181 262 NT NT 693
CM244 (CRF01_AE) 35 20 85 20 31 20 20 25 NT NT 693
a SHIV 89.6P was tested in the MT-2 assay; all other HIV isolates were tested in the M7-luciferase assay. HIV-1 isolates QH0692, SS1196, SF162, 6101, BX08,
BG1168, and BAL were assayed with post-injection 5 serum; other HIV-1 isolates were assayed with post-injection 4 serum.
b Prebleed values for sera with positive neutralization titers ranged from 20 to 69. All positive neutralization titers were 3-fold over background (boldface) and
were 30.
c HIV-positive serum was either a HIV-1-positive human serum (LEH03) or an anti-gp120 guinea pig serum (used only with isolate SS1196) with known neutralizing
activity for HIV-1 isolate SS1196. TriMab2 is a mixture of human MAbs 2F5, b12, and 2G12. Values for TriMab2 and CD4-IgG2 are in micrograms per milliliter.
d NT, not tested.
TABLE 3. Ability of group M consensus V3 peptides to absorb
CON6 gp120- induced neutralizing activity to T-cell line-adapted
HIV-1 MN and to HIV-1 primary isolates SS1196 and BX08
Guinea pig no. HIV-1Isolate
Neutralizing antibody titera
Before
absorption
After
absorption
%
Absorption
646 MN 6,166 2,309 63
647 MN 1,089 292 73
648 MN 1,364 195 86
649 MN 388 57 85
Mean 
 SEM 77 
 5
646 SS1196 1,408 406 68
647 SS1196 380 251 34
648 SS1196 469 195 58
649 SS1196 113 57 50
Mean 
 SEM 53 
 7
646 BX08 510 333 35
647 BX08 454 173 62
648 BX08 388 258 34
649 BX08 124 137 10
Mean 
 SEM 30 
 15
a Neutralizing titers are from the multiple-round luciferase assay as described
in Materials and Methods.
TABLE 4. Ability of group M consensus V3 peptides to absorb
CON6 gp140CF-induced neutralizing activity to T-cell line-adapted
HIV-1 MN and to HIV-1 primary isolates SS1196 and BX08
Guinea pig no. HIV-1Isolate
Neutralizing antibody titera
Before
absorption
After
absorption
%
Absorption
650 MN 2,179 168 94
651 MN 7,729 942 88
652 MN 3,400 954 72
653 MN 860 57 93
Mean 
 SEM 87 
 5
650 SS1196 644 46 93
651 SS1196 547 223 59
652 SS1196 506 256 49
653 SS1196 368 133 64
Mean 
 SEM 66 
 9
650 BX08 409 196 52
651 BX08 267 137 49
652 BX08 178 223 28
653 BX08 254 248 2
Mean 
 SEM 19 
 20
a Neutralizing titers are from the multiple-round luciferase assay as described
in Materials and Methods.
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ies with multiple strains of mice and with nonhuman pri-
mates are under way.
Many contemporary envelope glycoproteins express epi-
topes to which potent neutralizing human MAbs bind, yet
when used as immunogens themselves, they do not induce
broadly neutralizing anti-HIV-1 antibodies. Our neutralizing
antibody studies did demonstrate as proof of concept the abil-
ity of CON6 Envs to induce antibodies that weakly neutralized
selected HIV-1 primary isolates. However, it is also clear that
the primary isolates that are most difficult to neutralize (e.g.,
PAVO, 6101, BG1168, 92RW020, and CM244) were either
only weakly or not neutralized by anti-CON6 gp120 or
gp140CF sera (Table 2). For the TCLA strain MN and one of
two primary isolates tested (SS1196), antibodies to the group
M consensus V3 loop were responsible for the majority of the
neutralizing activity in both gp120 and gp140CF sera (Tables 3
and 4). Thus, for centralized envelopes such as CON6 to be
candidates as immunogens, significant improvements in con-
sensus Env immunogenicity will need to be made.
BN-PAGE analysis of CON6 gp120 and gp140CF showed
oligomer formation of CON6 gp140CF in the form of trimers
and tetramers. The similarity of neutralizing antibody re-
sponses induced by CON6 gp120 and gp140CF proteins indi-
cated that with the CON6 group M consensus protein, the
oligomeric form did not add enhanced immunogenicity. It will
be important to compare the neutralizing capacity of antibod-
ies induced by newer consensus Env proteins in which all
variable loops are consensus to that of the spectrum of neu-
tralizing antibodies induced by CON6 Envs.
Three computer models (consensus, ancestor, and center of
the tree) have been proposed to generate centralized HIV-1
genes (9, 10, 12, 19, 23, 24). The biology of HIV-1 gives rise to
star-like phylogenies, and as a consequence of this, the three
kinds of sequences are very similar to each other (10). Any of
the three will reduce the protein distances between immuno-
gens and field virus strains. In the case of the M group central
sequence studied here, distances to all subtypes and recombi-
nants are essentially reduced to intrasubtype levels (12, 24).
Within subtypes, distances are roughly halved (12). However,
given the fact that HIV-1 is diversifying under host immune
pressure, the small number of differences between the three
model sequences may be enriched for immunologically impor-
tant positions.
Consensus, ancestral, and center-of-the-tree sequences, de-
spite their similarities, have theoretical advantages and disad-
vantages (10, 12, 23). Global sequencing is generally conducted
with viruses sampled during chronic infections that have been
subjected to within-host immune pressure, not with transmit-
ted viruses sampled during acute infection. While consensus
sequences are arguably the most representative of current cir-
culating viral populations, ancestral and center-of-the-tree se-
quences hypothetically may have an advantage of recreating
potent epitopes that have tended to escape over time during
chronic infections but, for reasons of viral fitness and trans-
mission, tend to revert to a more ancestral form in a new host.
However, even phylogenetic reconstructions of center-of-the-
tree and ancestor sequences may miss such epitopes if they are
inadequately represented in the sequences sampled and used
to reconstruct the trees. Furthermore, focusing a vaccine re-
sponse on epitopes that for the most part have escaped and are
rare in a contemporary population may be a disadvantage, no
matter how potent the response to a particular epitope is.
Another potentially useful strategy would be to derive central
sequences by using only samples obtained during acute infec-
tion, but at this time such samples are inadequately repre-
sented in the database.
The CON6 env gene was our first prototype gene designed in
2000 from 1999 Los Alamos HIV sequence database se-
quences. A next-generation group M consensus env (CON-S)
has been generated based on 2000 database sequences. The
CON-S env gene contains minimum consensus variable regions
and is currently being tested for antigenicity and immunoge-
nicity. The data in our present study demonstrate that our
initial prototype consensus Env shares antigenic, functional,
and immunogenic properties with wild-type Env. Future stud-
ies with newer centralized Env sequences will determine the
full extent of breadth of T- and B-cell responses that can be
generated by centralized artificial genes.
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